The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

A Hepatitis Necessity: Quitting Alcohol

Back to News Homepage

Next

VA Model Improves Hep C Care

Two Modes of Action Explains Daclatasvir’s Potency

February 26, 2013

Print this page

Although still in development, Daclatasvir appears to cause the fastest decline in Hepatitis C viral load seen to date. A combined effort between mathematicians, clinicians and scientists has found that this drug has two, simultaneous modes of action.

New Study On Hepatitis C Drug Treatment in Vivo and in Vitro

Feb. 18, 2013 — Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs. An interdisciplinary effort by mathematical modelers, clinicians and molecular virologists has revealed that daclatasvir has two main modes of action against HCV and also yields a new, more accurate estimate of the HCV half-life.

Results of the NS5A study are published in the Proceedings of the National Academy of Sciences (PNAS) on February 18th, 2013.

Continue reading this entire article:
http://www.sciencedaily.com/releases/2013/02/130218164128.htm

7 Comments
Share
Share

Previous

A Hepatitis Necessity: Quitting Alcohol

Back to News Homepage

Next

VA Model Improves Hep C Care

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.